Guidelines and Policies
Abstracts can be considered for “Oral or Poster” OR “Poster ONLY.” Those who select “Poster ONLY” will not be considered for oral presentation within SITC’s Annual Meeting. Selecting “Oral or Poster” will allow you to be considered for oral presentation within the Annual Meeting and/or poster presentation.
Below are the guidelines for your abstract submission. The submitting author is responsible for assuring that the abstract adheres to these.
- Type the text unjustified without hyphenating words at line breaks
- Use single line spacing. Use hard returns only to end headings and paragraphs
- Abbreviations should be used as sparingly as possible and should be defined when first used
- All abstracts must be in English. Spelling within any one abstract should be US English or UK English, but not a mixture
- In most cases, Greek letters and other special characters will transfer from your word processing software via copy and paste functions. If you are unable to reproduce a particular special character, type out the name of the symbol in full
- SI units should be used throughout (liter and molar are permitted, however.)
The title must be entered exactly as it should appear and should be in sentence case. Do not put the title in quotes, underline it, or use punctuation. The title can be a maximum of 200 characters, including spaces.
Example: Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancer
All abstract submitters will be asked to indicate the primary category with which the abstract most closely aligns. This primary selection will aid the abstract reviewers in placing the abstract into the most appropriate session, if accepted for oral presentation. Accepted abstracts are also listed according to the primary category selected within the Annual Meeting Abstract Book, the JITC supplement and the Poster Hall.
Should the submitter believe more than one category is applicable, they can select a secondary category. The secondary category will only be used aid the abstract reviewers in placing the abstract into the most appropriate session, if accepted for oral presentation. The secondary category WILL NOT be used for the abstract listing in publications or placement in the Poster Hall.
All abstract submitters will be asked to indicate keywords for their abstract. Keywords are included in the Annual Meeting Abstract Book, website and app to assist users in searching for abstracts. Up to 10 keywords can be selected.
The following is included in the abstract body and must not exceed 400 words total:
*For Clinical Trials in Progress, results and conclusions are not required.
The following are not included in the 400-word limit.
Acknowledgements: Brief acknowledgements may be included.
Trial Registration: If applicable, abstracts related to randomized controlled clinical trials (RCTs) should include the trial registry along with the unique identifying number. Trial registers that currently meet the publisher’s requirements can be found here.
References: Citations to references should be included in square brackets [1,2]. All references need corresponding citations in the text, and vice versa.
Journal abbreviations should follow MEDLINE standards. References should be laid out at the end of the abstract.
Lastname A, Lastname B, Lastname C. Title of journal article. Journal Medline abbreviation. Year; Volume:first page-last page.
Chomczynski P, Sacchi N, Single-step method of RNA isoloation by acid guanidinium thiocyanate-phernol-chloroform extraction. Anal Biochem. 1987;162:156-159.
Web links (URLs) should be provided in full, including both the title of the site and the URL.
Ethics Approval: If the abstract discusses studies involving human subjects, human material, or human data, or involving animals, an ethics statement should be included: "The study was approved by XYZ intuition’s Ethics Board, approval number 12345."
Consent: If applicable, for abstracts containing sensitive or identifiable information, written consent to publish must be obtained from the study participant(s) by authors. In these cases authors should include a ‘consent’ section in their abstract and SITC recommends using the following wording: “Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.”
Authors and Institutions
All authors and contact information must be listed in the correct order. The order in which authors will be listed in the author block of all publications including online, the Annual Meeting Abstract Book, and the JITC Supplement is the order that they are entered.
Each author MUST indicate at least one institution affiliation. Affiliations should include Department, University, Town, State, USA OR Institution, Town, Country, for example:
1Pathology Department, New York School of Medicine, New York, NY, USA
2Roche Innovation Center Penzberg, Penzberg, Germany
Your submission needs to have a minimum of:
- 1 Corresponding Author
- 1 Presenting Author
- 1 Primary Author
The presenting author will need to complete a Conflicts of Interest Disclosure Form. Once the abstract is submitted, the presenting author will be sent an email notification to complete the form.
The corresponding author will be highlighted and their email provided in the JITC supplement.
There is no limit to the number of authors you can include.
The author submitting an abstract to the 34th Annual Meeting & Pre-Conference Programs (SITC 2019) must agree to the following:
- Serve as the contact for all correspondence about the abstract and inform co-authors about its status
- Confirm all authors are aware of and agree to the content and data presented in the abstract
- Verify the abstract is accurate and that permission has been obtained from all relevant parties
- Verify the abstract has not been published prior to SITC 2019, or if previously published, contains significant new data
- Agree that the full abstract content submitted to SITC 2019 is embargoed until 8 a.m. ET on Nov. 5, 2019
- Agree to release of the abstract title prior to the SITC embargo date and time of 8 a.m. ET on Nov. 5, 2019. Regular abstract titles will be released on Oct. 1, 2019 and late-breaking abstract titles will be release on Nov. 1, 2019
- Agree to follow all media and press release policies set forth by SITC
Tables, Figures and Images
- Tables, figures and images should be numbered (ie: Table 1, Figure 1, or Image 1) in the title field with an optional caption
- The title and caption are not include in the total abstract word count
- All figures, tables, and images need corresponding citations in the text. Citations to any figures (Figure 1), tables (Table 1) or images (Image 1) must also be included in round brackets. All figures and tables need corresponding citations in the text, and vice versa
- There is not a limit to the number of figures that can be included
- Figures must be supplied electronically at 300 dpi minimum (600 dpi preferred)
- Do not include figures with embedded hyperlinks
- The following file types will be accepted: .png, .jpg, .gif
Late-Breaking Abstracts: Late-breaking abstract applications will need to indicate if it is a clinical or lab-based study and will need to include the following information in their application:
- Closure date of the study
- Primary clinical endpoint for analysis
- Type of analysis
- Provide an explanation why the experiment(s) could not be completed before the regular abstract submission deadline, Aug. 1, 2019, and needs to be considered for late-breaking submission
Young Investigator Awards Abstracts: Submitters of abstracts that qualify for a Young Investigator Award and indicate they would like to be considered for a Young Investigator Award must include the following information in their application:
- Upload a letter of recommendation from a supervisor (.doc, .docx, .pdf)
- Confirm they are a SITC member
- Confirm they are a student, postdoctoral research fellow, clinical fellow, or junior faculty with three or fewer years on staff, and if so, identify which category they represent
- Indicate the percentage of contribution by the primary and presenting author in regards to conception and design, collection and assembly, data analysis and interpretation, and abstract writing
Late-Breaking Abstract Information and Eligibility
Late-breaking abstract submission is solely for abstracts with late-breaking data and not for abstracts submitted “late.” The late-breaking abstract deadline is not intended to be an extension of the general submission deadline. Late-breaking abstracts highlight novel and practice-changing studies, and only apply to data that would have not otherwise have been presented as an abstract at SITC 2019.
Examples of acceptable late-breaking abstracts include the following (in each case, results were not available or significant by the regular abstract submission deadline):
- Results of a practice-changing prospective Phase III clinical trial
- Phase II study showing anti-tumor activity in a novel context
- An early clinical trial with novel proof-of-principle data
- Demonstration of novel cancer biology with therapeutic implications
For clinical studies, authors need to justify late consideration by documenting the closure date of the study, and submit a late-breaking abstract application by the regular abstract submission deadline (Aug. 1, 2019). This application needs to include necessary abstract information (without results and conclusions) and incorporate the primary clinical endpoint for analysis, type of analysis, date of planned analysis, and planned statistical methods for analysis.
Laboratory-based studies need to be justified within the author's late-breaking abstract application. Authors need to specify why experiments could not be completed before the standard abstract deadline.
The data in the abstract must not be published prior to SITC 2019.
Late-breaking abstracts are considered for, but not limited to, oral abstract presentations during the Late-Breaking Abstract Sessions from 12:00 – 12:30 p.m. on Friday, Nov. 8, 2019 and 11:50 a.m. – 12:20 p.m. on Saturday, Nov. 9, 2019.
Below are the policies of the SITC abstract submission process. By submitting an abstract, you are agreeing to abide by these policies.
Abstract Embargo & Release Information Policy
Regular and Late-Breaking Abstract Titles
Titles for regular abstracts will be available on Oct. 1, 2019 and titles for late-breaking abstracts will be available on Nov. 1, 2019 on the SITC Annual Meeting website and app. Once abstract titles are listed on the website, press releases can be issued with the titles and logistical information.
Regular and Late-Breaking Abstract Content
Full regular and late-breaking abstract content will be embargoed until 8 a.m. ET on Nov. 5, 2019. This includes content within the original abstract submitted, additional data that was available on a poster of the abstract and/or any updated and/or any new data that will be available in oral presentations in SITC’s Annual Meeting.
Press Release Policy
Any planned press releases and media alerts must have been reviewed and approved in advance by SITC Communications staff. Please provide a minimum for two business days for review. Drafts should be emailed to firstname.lastname@example.org.
For press releases about abstracts aimed at being released:
- Before 8 a.m. ET on Nov. 5, 2019: Press releases should be issued with only logistical information (abstract title, author, poster number, and presentation date and time) about an abstract/poster/oral presentation
- After 8 a.m. ET on Nov. 5, 2019: Press releases should be issued with information about the content within the original abstract submitted, additional data that will be available on a poster of the abstract and/or any updated and/or new data that will be available in oral presentation at SITC’s Annual Meeting
Withdrawal & Editing Policy
The deadline for regular abstract withdrawal or changes, including presenter changes, is Sept. 6, 2019. The deadline for late-breaking abstract withdrawal or changes, including presenter changes, is Sept. 30, 2019. These deadlines are set in place because the abstract information is pulled for publication immediately following these dates and cannot be edited after that. If you would like to withdraw or make a change to your abstract between the submission deadline and this date, you must submit your request in writing to email@example.com. Upon receipt of your request SITC will make the change, if possible, and send a confirmation once the withdrawal or change has been completed.
regarding providing your information on SITC platforms and our
service providers, including the Abstract Management System provided by Planstone.
Call for Papers by Publisher
BioMed Central Ltd. (BMC), the publisher of the Journal for ImmunoTherapy of Cancer (JITC), reserves
the right to email corresponding authors of abstracts or late-breaking abstract once they are published
to notify them of online publication and to invite them to submit articles to JITC o other journals
published by Springer Nature.
In consideration of Publication of the abstract, abstract submitter agree to abide by the
publisher’s copyright policy
and grant SITC and their successors or assigns a license
to publish the article
and identify itself as the original publishing entity. Properly cited, SITC is granted all rights – including
those now or hereafter protected by the copy right laws of the United States and all foreign countries,
as well as any renewal, extension or reversion of copyright, now or hereinafter provided in an country –
to any materials developed while promoting and repurposing the abstract. Abstract submitters also
warrant that their contribution is an original work not published elsewhere, or if previously published
contains significant new data, and that they have full power to grant these rights.
Encore Presentation Policy
Any abstract that has been previously accepted and/or published (by any meeting or publisher) must contain substantial new data in order to be considered. Contact firstname.lastname@example.org with any questions pertaining to substantial new data.